

- Knapke S, Nagarajan R, Correll J, et al. Hereditary cancer risk assessment in a pediatric follow-up clinic. *Pediatr Blood Cancer* 2012;58:85–89.
- Choong SC, Priest JR, Foulkes WD. Exploring the endocrine manifestations of DICER1 mutations. *Trends Mol Medicine* 2012;18:503–505.
- Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. *Proc Natl Acad Sci U S A* 1971;68:820–823.
- Comings DE. A general theory of carcinogenesis. *Proc Natl Acad Sci U S A* 1973;70:3324–3328.
- Devesa SS. The incidence of retinoblastoma. *Am J Ophthalmol* 1975;80:263–265.
- Knudson AG Jr, Hethcote HW, Brown BW. Mutation and childhood cancer: a probabilistic model for the incidence of retinoblastoma. *Proc Natl Acad Sci U S A* 1975;72:5116–5120.
- Smith LM, Donaldson SS, Egbert PR, et al. Aggressive management of second primary tumors in survivors of hereditary retinoblastoma. *Int J Radiat Oncol Biol Phys* 1989;17:499–505.
- Cavenee WK, Dryja TP, Phillips RA, et al. Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. *Nature* 1983;305:779–784.
- Squire J, Dryja TP, Dunn J, et al. Cloning of the esterase D gene: a polymorphic gene probe closely linked to the retinoblastoma locus on chromosome 13. *Proc Natl Acad Sci U S A* 1986;83:6573–6577.
- Friend SH, Bernards R, Rogelj S, et al. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. *Nature* 1986;323:643–646.
- Bookstein R, Shew JY, Chen PL, et al. Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene. *Science* 1990;247:712–715.
- Burkart DL, Sage J. Cellular mechanism of tumor suppression by the retinoblastoma gene. *Nature Rev Cancer* 2008;8:671–682.
- Laurie NA, Donovan SL, Shih CS, et al. Inactivation of the p53 pathway in retinoblastoma. *Nature* 2006;444:61–66.
- Reed D, Shen Y, Shelat A, et al. Identification and characterization of the first small molecule inhibitor of MDMX. *J Biol Chem* 2010;285:10786–10796.
- Marine JC, Dyer MA, Jochemsen AG. MDMX: from bench to bedside. *J Cell Science* 2007;120:371–378.
- Matsunaga E. Hereditary retinoblastoma: penetrance, expressivity and age of onset. *Hum Genet* 1976;33:1–15.
- Schubert EL, Strong LC, Hansen MF. A splicing mutation in RB1 in low penetrance retinoblastoma. *Br J Cancer* 1986;53:661.
- Janeway KA, Kim SY, Lodish M, et al. Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. *Proc Natl Acad Sci U S A* 2011;108:314–318.
- McWhinney SR, Pasini B, Stratakis CA. Familial gastrointestinal stromal tumors and germ-line mutations. *N Engl J Med* 2007;357:1054–1056.
- Agaram NP, Laquaglia MP, Ustun B, et al. Molecular characterization of pediatric gastrointestinal stromal tumors. *Clin Cancer Res* 2008;14:3204–3215.
- Killian JK, Kim SY, Miettinen M, et al. Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor. *Cancer Discovery* 2013;3:648–657.
- Stumpf GR, Alkane JF, Annegers JF, et al. Neurofibromatosis. *Arch Neurol* 1988;45: 575.
- Riccardi VM, Eichner JE. *Neurofibromatosis: Phenotype, Natural History and Pathogenesis*. Baltimore: Johns Hopkins University Press; 1986.
- Halliday AL, Sobel RA, Martuza RL. Benign spinal nerve sheath tumors: their occurrence sporadically and in neurofibromatosis types 1 and 2. *J Neurosurg* 1991;74:248–253.
- Marchuk DA, Saulino AM, Tavakkol R, et al. cDNA cloning of the type 1 neurofibromatosis gene: complete sequence of the NF1 gene product. *Genomics* 1991;11:931–940.
- DeClure JE, Cohen BD, Lowy DR. Identification and characterization of the neurofibromatosis type 1 protein product. *Proc Natl Acad Sci U S A* 1991; 88:9914–9918.
- Viskochil D, Buchberg AM, Xu G, et al. Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. *Cell* 1990;62:187–192.
- Dasgupta B, Yi Y, Chen DY, et al. Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors. *Cancer Res* 2005;65:2755–2760.
- Jessen WJ, Miller SJ, Jousma E, et al. MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. *J Clin Invest* 2013;123:340–347.
- Martuza RL, Eldridge R. Neurofibromatosis 2 (bilateral acoustic neurofibromatosis). *N Engl J Med* 1988;318:684–688.
- Trofatter JA, MacCollin MM, Rutter JL, et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. *Cell* 1993;73:791–800.
- Rouleau GA, Merel P, Lutchman M, et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neurofibromatosis type 2. *Nature* 1993;363:515–521.
- Hara T, Bianchi AB, Seizinger BR, et al. Molecular cloning and characterization of alternatively spliced transcripts of the mouse neurofibromatosis 2 gene. *Cancer Res* 1994;54:330–335.
- Lin AL, Gutmann DH. Advances in the treatment of neurofibromatosis-associated tumours. *Nat Rev Clin Oncol* 2013;10:616–624.
- Brodeur GM, Sekhon G, Goldstein MN. Chromosomal aberrations in human neuroblastomas. *Cancer* 1977;40:2256–2263.
- Fujita T, Igarashi J, Okawa ER, et al. CHD5, a tumor suppressor gene deleted from 1p36 in neuroblastoma. *J Natl Cancer Inst* 2008;100:940–949.
- Munirajan AK, Avdo K, Mukai A, et al. KIF1Bbeta functions as a haploinsufficient tumor suppressor gene mapped to chromosome 1p36.2 by inducing apoptotic cell death. *JBC* 2008;283:2426–24434.
- Caron H, van Sluis P, de Kraker J, et al. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. *N Engl J Med* 1996;334:225–230.
- Lau L, Hansford LM, Cheng LS, et al. Cyclooxygenase inhibitors modulate the p53/HDM2 pathway and enhance chemotherapy-induced apoptosis in neuroblastoma. *Oncogene* 2007;26:1920–1931.
- Irvin MS, Kaelin WC. p53 family update: p73 and p63 develop their own identities. *Cell Growth Differ* 2001;12:337–349.
- Melino G, De Laurenzi V, Vousden KH. p73: Friend or foe in tumorigenesis. *Nat Rev Cancer* 2002;2:605–615.
- Casciano I, Mazzocco K, Boni L, et al. Expression of DeltaNp73 is a molecular marker for adverse outcome in neuroblastoma patients. *Cell Death Differ* 2002;9:246–251.
- Douc-Rasy S, Barrois M, Echeyne M, et al. DeltaN-p73alpha accumulates in human neuroblastic tumors. *Am J Pathol* 2002;160:631–639.
- Biedler JL, Ross R, Sharske S, et al. Human neuroblastoma cytogenetics: search for significance of homogeneously staining regions in double minute chromosomes. In: Evans AE, ed. *Advances in Neuroblastoma Research*. New York: Raven; 1980:81.
- Schwab M, Alitalo K, Klempnauer KH, et al. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. *Nature* 1983;305:245–248.
- Thiele CJ, Reynolds CP, Israel MA. Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma. *Nature* 1985;313:404–406.
- Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. *N Engl J Med* 1999;341:1165–1173.
- Schwab M, Ellison J, Busch M, et al. Enhanced expression of the human gene N-myc consequent to amplification of DNA may contribute to malignant progression of neuroblastoma. *Proc Natl Acad Sci U S A* 1984;81:4940–4944.
- Nakagawara A, Arima-Nakagawara M, Scavarda NJ, et al. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. *N Engl J Med* 1993;328:847–854.
- Ho R, Eggert A, Hishiki T, et al. Resistance to chemotherapy mediated by TrkB in neuroblastomas. *Cancer Res* 2002;62:6462–6466.
- Jaboin J, Kim CJ, Kaplan DR, et al. Brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from chemotherapy-induced apoptosis via phosphatidylinositol 3'-kinase pathway. *Cancer Res* 2002;62:6756.
- Norris MD, Bordow SB, Marshall GM, et al. Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. *N Engl J Med* 1996;334:231–238.
- Islam A, Kageyama H, Takada N, et al. High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factor and promotes cell survival in human neuroblastoma. *Oncogene* 2000;19:617–623.
- Trochet D, Bourdeaut F, Janoueix-Lorosey I, et al. Germ-line mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma. *Am J Hum Genet* 2004;74:761–764.
- Mosse YP, Laduenlager M, Longo L, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. *Nature* 2008;455:930–935.
- Janoueix-Lorosey I, Lequin D, Bruggieres L, et al. Somatic and germline activation mutations in the ALK kinase receptor in neuroblastoma. *Nature* 2008;455:967–970.
- George RE, Sanda T, Hanna M, et al. Alkylating mutations in ALK provide a therapeutic target in neuroblastoma. *Nature* 2008;455:975–978.
- Chen Y, Takita J, Choi YL, et al. Oncogenic mutations of ALK kinase in neuroblastoma. *Nature* 2008;477:971–974.
- Mosse YP, Lim MS, Voss SD, et al. Safety and activity of crizotinib for pediatric patients with refractory solid tumors or anaplastic large cell lymphoma: a COG phase I consortium study. *Lancet Oncol* 2013;14:472–480.
- Attiyeh EF, London WB, Mosse YP, et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. *N Engl J Med* 2005;353:2243–2253.
- Binz N, Shalaby T, Rivera P, et al. Telomerase inhibition, telomere shortening, cell growth suppression and induction of apoptosis by telomestatin in childhood neuroblastoma cells. *Eur J Cancer* 2005;41:2873–2881.
- Ohali A, Avigad S, Ash S, et al. Telomere length is a prognostic factor in neuroblastoma. *Cancer* 2006;107:1391–1399.
- Ewing J. Classics in oncology. Diffuse endothelioma of bone: proceedings of the New York Pathological Society, 1921. *CA Cancer J Clin* 1972;22:95–98.
- Ture-Carel C, Aurias A, Mugneret F, et al. Chromosomes in Ewing's sarcoma. I. An evaluation of 85 cases of remarkable consistency of t(11;22)(q24;q12). *Cancer Genet Cytogenet* 1988;32:229.
- Whang-Peng J, Triche T, Knutsen T, et al. Chromosome translocation in peripheral neuroepithelioma. *N Engl J Med* 1984;311:584–585.

66. Delattre O, Zucman J, Ploustael B, et al. Gene fusion with an ETS DNA binding domain caused by chromosome translocation in human cancers. *Nature* 1992;359:162–165.
67. Zucman J, Delattre O, Desmaziere C, et al. Cloning and characterization of the Ewing's sarcoma and peripheral neuroepithelioma t(11;22) translocation breakpoints. *Genes Chromosomes Cancer* 1992;5:271–277.
68. May WA, Gishizky ML, Lessnick SL, et al. Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation. *Proc Natl Acad Sci U S A* 1993; 90:5752–5756.
69. Sorensen PH, Lessnick SL, Lopez-Terrada D, et al. A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERC. *Nat Genet* 1994;6:146–151.
70. Jeon IS, Davis JN, Braun BS, et al. A variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1. *Oncogene* 1995;10: 1229–1234.
71. Kaneko Y, Yoshida K, Handa M, et al. Fusion of an ETS-family gene, EIAF, to EWS by t(17;22)(q12;q12) chromosome translocation in an undifferentiated sarcoma of infancy. *Genes Chromosomes Cancer* 1996;15:115.
72. Peter M, Couturier J, Pacquement H, et al. A new member of the ETS family fused to EWS in Ewing tumors. *Oncogene* 1997;14:1159–1164.
73. de Alava E, Kawai A, Healey J, et al. EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma. *J Clin Oncol* 1998;16:1248–1255.
74. Le Deley MC, Delattre O, Schaefer KL, et al. Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial. *J Clin Oncol* 2010;28:1982–1988.
75. van Doorninck JA, Ji L, Schaub B, et al. Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma: a report from the Children's Oncology Group. *J Clin Oncol* 2010;28:1989–1994.
76. Hahm KB, Cho K, Lee C, et al. Repression of the gene encoding the TGF-beta type II receptor is a major target of the EWS-FLI1 oncoprotein. *Nat Genet* 1999;23:222–227.
77. Lessnick SL, Dacwag CS, Golub TR. The Ewing's sarcoma oncoprotein EWS/FLI1 induces a p53-dependent growth arrest in primary human fibroblasts. *Cancer Cell* 2002;1:393–401.
78. Deneen B, Denny CT. Loss of p16 pathways stabilizes EWS/FLI1 expression and complements EWS/FLI1 mediated transformation. *Oncogene* 2001; 20:6731–6741.
79. Smith R, Owen LA, Trem DJ, et al. Expression profiling of EWS/FLI1 identifies NKX2.2 as a critical target gene in Ewing's sarcoma. *Cancer Cell* 2006;9:405–416.
80. Kinsey M, Smith R, Lessnick SL. NR0B1 is required for the oncogenic phenotype mediated by EWS/FLI1 in Ewing's sarcoma. *Mol Cancer Res* 2006; 4:851–859.
81. Gangwal K, Sankar S, Hollenhorst PC, et al. Microsatellites as EWS/FLI1 response elements in Ewing's sarcoma. *Proc Natl Acad Sci U S A* 2008;105: 10149–10154.
82. Parham DM, Webber B, Holt H, et al. Immunohistochemical study of childhood rhabdomyosarcomas and related neoplasms: results of an Intergroup Rhabdomyosarcoma Study Project. *Cancer* 1991;67:3072–3080.
83. Dodd S, Malone M, McCulloch W. Rhabdomyosarcoma in children: a histological and immunohistochemical study of 59 cases. *J Pathol* 1989;158:13–18.
84. Dias P, Parham DM, Shapiro DN, et al. Myogenic regulatory protein (MyoD1) expression in childhood solid tumors: diagnostic utility in rhabdomyosarcoma. *Am J Pathol* 1990;137:1283–1291.
85. El-Badry OM, Minniti C, Kohn EC, et al. Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors. *Cell Growth Differ* 1990;1:325–331.
86. Minniti CP, Tsokos M, Newton WA Jr, et al. Specific expression of insulin-like growth factor-II in rhabdomyosarcoma tumor cells. *Am J Clin Pathol* 1994;101: 198–203.
87. Scrabble H, Witte D, Lampkin B, et al. Chromosomal localization of the human rhabdomyosarcoma locus by mitotic recombination mapping. *Nature* 1987;329:645–647.
88. Scrabble H, Witte D, Shimada H, et al. Molecular differential pathology of rhabdomyosarcoma. *Genes Chromosomes Cancer* 1989;1:23–35.
89. Scrabble H, Cavenee W, Ghavimi F, et al. A model for embryonal rhabdomyosarcoma tumorigenesis that involves genome imprinting. *Proc Natl Acad Sci U S A* 1989;86:7480–7484.
90. Rainier S, Johnson LA, Dobry CJ, et al. Relaxation of imprinted genes in human cancer. *Nature* 1993;362:747–749.
91. Ogawa O, Eccles MR, Szeto J, et al. Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms' tumour. *Nature* 1993;362:749–751.
92. Zhan S, Shapiro DN, Helman LJ. Activation of an imprinted allele of the insulin-like growth factor II gene implicated in rhabdomyosarcoma. *J Clin Invest* 1994;94:445–448.
93. Zhan S, Shapiro D, Zhang L, et al. Concordant loss of imprinting of the human insulin-like growth factor II gene promoters in cancer. *J Biol Chem* 1995;270:27983–27986.
94. Douglass EC, Valentine M, Eteubanas E, et al. A specific chromosomal abnormality in rhabdomyosarcoma. *Cytogenet Cell Genet* 1987;45:148–155.
95. Barr FG, Galili N, Holick J, et al. Rearrangement of the PAX3 paired box gene in the paediatric solid tumour alveolar rhabdomyosarcoma. *Nat Genet* 1993;3:113–117.
96. Shapiro DN, Sublett JE, Li B, et al. Fusion of PAX3 to a member of the forkhead family of transcription factors in human alveolar rhabdomyosarcoma. *Cancer Res* 1993;53:5108–5112.
97. Davis RJ, D'Cruz CM, Lovell MA, et al. Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma. *Cancer Res* 1994;54:2869–2872.
98. Williamson D, Missiaglia E, de Reyniès A, et al. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. *J Clin Oncol* 2010;28:2151–2158.
99. Chen X, Stewart E, Shelat AA, et al. Targeting oxidative stress in embryonal rhabdomyosarcoma. *Cancer Cell* 2013;24:710–724.
100. Shern JF, Chen L, Chmielecki J, et al. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. *Cancer Discov* 2014;4: 216–231.
101. Renshaw J, Taylor KR, Bishop R, et al. Dual blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo. *Clin Cancer Res* 2013;19:5940–5951.
102. Li FP, Fraumeni JF Jr. Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome. *J Natl Cancer Inst* 1969;43:1365–1373.
103. Li FP, Fraumeni JF Jr, Mulvihill JJ, et al. A cancer family syndrome in twenty-four kindreds. *Cancer Res* 1988;48:5358–5362.
104. Nichols KE, Malkin D, Carber JE, et al. Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. *Cancer Epidemiol Biomarkers Prev* 2001;10:83–87.
105. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. *Science* 1990;250:1233–1238.
106. Srivastava S, Zou ZQ, Pirolo K, et al. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. *Nature* 1990;348:747–749.
107. Varley JM, Thorncroft M, McGown G, et al. A detailed study of loss of heterozygosity on chromosome 17 in tumours from Li-Fraumeni patients carrying a mutation to the TP53 gene. *Oncogene* 1997;14:865–871.
108. Leroy B, Fournier JL, Ishioka C, et al. The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis. *Nucl Acids Res* 2013;41:D962–D969.
109. Bell DW, Varley JM, Szydlow TE, et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. *Science* 1999;286:2528–2531.
110. Bougeard G, Limacher JM, Martin C, et al. Detection of 11 germline inactivating TP53 mutations and absence of TP63 and HCHK2 mutations in 17 French families with Li-Fraumeni or Li-Fraumeni-like syndrome. *J Med Genet* 2001;38:253–257.
111. Diller L, Sexsmith E, Gottlieb A, et al. Germline p53 mutations are frequently detected in young children with rhabdomyosarcoma. *J Clin Invest* 1995;95:1606–1611.
112. McIntyre JF, Smith-Sorensen B, Friend SH, et al. Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma. *J Clin Oncol* 1994;12:925–930.
113. Hettmer S, Archer NM, Somers GR, et al. Anaplastic rhabdomyosarcoma in TP53 germline mutation carriers. *Cancer* 2014;120:1068–1075.
114. Rausch T, Jones DT, Zapotka M, et al. Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. *Cell* 2012;148:59–71.
115. Wagner J, Portwine C, Rabin K, et al. High frequency of germline p53 mutations in childhood adrenocortical cancer. *J Natl Cancer Inst* 1994;86:1707–1710.
116. Varley JM, McGown G, Thorncroft M, et al. Are there low-penetrance TP53 alleles? Evidence from childhood adrenocortical tumors. *Am J Hum Genet* 1999;65:995–1006.
117. Chompret A, Brugieres L, Ronsin M, et al. P53 germline mutations in childhood cancers and cancer risk for carrier individuals. *Brit J Cancer* 2001;82:1932–1937.
118. Tinat J, Bougeard G, Baert-Desurmont S, et al. 2009 version of the Chompret criteria for Li-Fraumeni syndrome. *J Clin Oncol* 2009;27:e108–e109.
119. Ribeiro RC, Sandrini F, Figueiredo B, et al. An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. *Proc Natl Acad Sci U S A* 2001;98:9330–9335.
120. DiGiannarino EL, Lee AS, Cadwell C, et al. A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer. *Nat Struct Biol* 2002;9:12–16.
121. Olivier M, Goldgar DE, Sodha N, et al. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. *Cancer Res* 2003;63:6643–6650.
122. Tabori U, Nanda S, Druker H, et al. Younger age of cancer initiation is associated with shorter telomere length in Li-Fraumeni syndrome. *Cancer Res* 2007;67:1415–1418.
123. Marcel V, Palmero EI, Falagan-Lotsch P, et al. TP53 PIN 3 and MDM2 SNP309 polymorphisms as genetic modifiers in the Li-Fraumeni syndrome: impact on age at first diagnosis. *J Med Genet* 2009;46:766–772.

124. Shlien A, Tabori U, Marshall CR, et al. Excessive genomic DNA copy number variation in the Li-Fraumeni cancer predisposition syndrome. *Proc Natl Acad Sci U S A* 2008;105:11264–11269.
125. Clericuzio CL, Johnson C. Screening for Wilms tumor in high-risk individuals. *Hematol Oncol Clin North Am* 1995;9:1253–1265.
126. Sotelo-Avila C, Gonzalez-Crussi F, Fowler JW. Complete and incomplete forms of Beckwith-Wiedemann syndrome: their oncogenic potential. *J Pediatr* 1980;96:47–50.
127. Mannens M, Hoovers JM, Redeker E, et al. Parental imprinting of human chromosome region 11p15.3-pter involved in the Beckwith-Wiedemann syndrome and various human neoplasia. *Eur J Hum Genet* 1994;2:3–23.
128. Engel JR, Smallwood A, Harper A, et al. Epigenetic-phenotype correlations in Beckwith-Wiedemann syndrome. *J Med Genet* 2000;37:921–926.
129. Henry I, Bonaiti-Pellie C, Chehense V, et al. Uniparental paternal disomy in a genetic cancer-predisposing syndrome. *Nature* 1991;351:665–667.
130. Reik W, Brown KW, Schneid H, et al. Imprinting mutations in the Beckwith-Wiedemann syndrome suggested by altered imprinting pattern in the IGF2-H19 domain. *Hum Mol Genet* 1995;4:2379–2385.
131. Li M, Squire J, Shuman C, et al. Imprinting status of 11p15 genes in Beckwith-Wiedemann syndrome patients with CDKN1C mutations. *Genomics* 2001;74:370–376.
132. Feinberg AP. Genomic imprinting and gene activation in cancer. *Nat Genet* 1993;4:110–113.
133. Gorlin RJ. Nevoid basal-cell carcinoma syndrome. *Medicine (Baltimore)* 1987;66:98–113.
134. Gailani MR, Stahle-Backdahl M, Leffell DJ, et al. The role of the human homologue of *Drosophila patched* in sporadic basal cell carcinomas. *Nat Genet* 1996;14:78–81.
135. Hahn H, Wicking C, Zaphiropoulos PG, et al. Mutations of the human homologue of *Drosophila patched* in the nevoid basal cell carcinoma syndrome. *Cell* 1996;85:841–851.
136. Cowan R, Hoban P, Kelsey A, et al. The gene for the naevoid basal cell carcinoma syndrome acts as a tumour-suppressor gene in medulloblastoma. *Br J Cancer* 1997;76:141–145.
137. Hahn H, Wojnowski L, Zimmer AM, et al. Rhabdomyosarcomas and radiation hypersensitivity in a mouse model of Gorlin syndrome. *Nat Med* 1998;4:619–622.
138. Zhan S, Helman LJ. Glimpsing the cause of rhabdomyosarcoma. *Nat Med* 1998;4:559–560.
139. Parham DM, Weeks DA, Beckwith JB. The clinicopathologic spectrum of putative extrarenal rhabdoid tumors. An analysis of 42 cases studied with immunohistochemistry or electron microscopy. *Am J Surg Pathol* 1994;18:1010–1029.
140. Versteeg I, Sevenet N, Lange J, et al. Truncating mutations of hSNF5/IN11 in aggressive paediatric cancer. *Nature* 1998;394:203–206.
141. Grand F, Kulkarni S, Chase A, et al. Frequent deletion of hSNF5/IN11, a component of the SWI/SNF complex, in chronic myeloid leukemia. *Cancer Res* 1999;59:3870–3874.
142. Sevenet N, Sheridan E, Amram D, et al. Constitutional mutations of the hSNF5/IN11 gene predispose to a variety of cancers. *Am J Hum Genet* 1999;65:1342–1348.
143. Biegel JA, Zhou JY, Rorke LB, et al. Germ-line and acquired mutations of IN11 in atypical teratoid and rhabdoid tumors. *Cancer Res* 1999;59:74–79.
144. Choong SC, Priest JR, Foulkes WD. Exploring the endocrine manifestations of DICER1 mutations. *Trends Mol Medicine* 2012;18:503–505.
145. Field M, Shanley S, Kirk J. Inherited cancer susceptibility syndromes in pediatric practice. *J Paediatr Child Health* 2007;43:219–229.
146. Villani A, Tabori U, Schiffman JD, et al. Biochemical and imaging surveillance in TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study. *Lancet Oncology* 2011;12:559–567.
147. Jasperson KW, Kohlmann W, Gammon A, et al. Role of rapid sequence whole body MRI screening in SDH-associated hereditary paraganglioma families. *Fam Cancer* 2013;13:257–265.
148. Moore SW, Appfelstaedt J, Zaahl MG. Familial medullary carcinoma prevention, risk evaluation, and RET in children of families with MEN2A. *J Pediatr Surg* 2007;42:326–332.
149. Grosfeld FJ, Beemer FA, Lips CJ, et al. Parents' responses to disclosure of genetic test results of their children. *Am J Med Genet* 2000;94:316–323.
150. Michie S, Bobrow M, Marteau TM. Predictive genetic testing in children and adults: a study of emotional impact. *J Med Genet* 2001;38:519–526.
151. Lammens C, Bleiker Aaronson N, Aaronson N, et al. Attitudes towards pre-implantation genetic diagnosis for hereditary cancer. *Fam Cancer* 2009;8:457–464.
152. Malkin D. Prenatal diagnosis, preimplantation genetic diagnosis and cancer: was Hamlet wrong? *J Clin Oncol* 2009;27:4446–4447.
153. Roth MT, Painter RB. Genetic discrimination in health insurance: an overview and analysis of the issues. *Nurs Clin North Am* 2000;35:731–756.